| Patent application number | Description | Published |
|---|
| 20090059952 | APPARATUS AND METHOD FOR MANAGING ACCESS TO ONE OR MORE NETWORK RESOURCES - An apparatus is provided that includes a processor configured to receive a captured traffic unit (CTU) intended for a network service, the CTU being one into which incoming traffic has been assembled based on a filter describing which incoming traffic to capture and how to assemble the respective incoming traffic into the CTU. The processor is also configured to determine whether to allow the CTU to pass to one or more applications configured to implement the respective network service based on a passlet including permissions to a particular user. The processor is further configured to instruct a firewall to allow the CTU to pass to the respective one or more applications or to reject the CTU based on the determination. In this regard, the processor is configured to perform the above functions under control of a security framework implemented in middleware between a user-level domain and a system-level domain. | 03-05-2009 |
| 20090063691 | Access rights used for resource discovery in peer-to-peer networks - Secure resource discover in peer-to-peer networks involves creating a resource discovery record associated with a computing resource of a user device that is made available via the user device to peers of a peer-to-peer network. The resource discovery record describes the computing resource and may be independent of native service discovery mechanisms of the peer-to-peer network. An access right record is created that controls the ability of one or more contacts to gain access to the resource discovery record. The resource discovery record is sent to the one or more contacts via the peer-to-peer network. The one or more contacts can use the resource discovery record to access the computing resource via the peer-to-peer network in accordance with the access right record. | 03-05-2009 |
| 20090222517 | Methods, systems, and apparatus for using virtual devices with peer-to-peer groups - Using virtual devices with P2P groups involves sending a discovery record from a virtual device to an Internet-based broker. A registration message from the peer-to-peer group is received by the virtual device in response to the discovery record. The registration message is used to join the virtual device with the peer-to-peer group. The user is authorized via the Internet-based broker and the virtual device is joined with the peer-to-peer group based on the user authorization and the registration message. Services are then provided to the peer-to-peer group via the virtual device in accordance with the discovery record. The virtual device may include a wide-area network service that is modeled to act as a physical device of the peer-to-peer group. | 09-03-2009 |
| 20090288138 | Methods, systems, and apparatus for peer-to peer authentication - Peer-to-peer authentication involves generating an authenticatable, globally unique, peer-to-peer identifier to associate a device with a user identity. The user identity is associated with one or more peer devices of a user. The peer-to-peer identifier, together with authentication credentials of a legacy Internet service, is sent to an infrastructure authentication service. The legacy Internet service is capable of verifying the user identity based on the authentication credentials. Based on verification of the authentication credentials, a list of authenticatable, globally unique, peer-to-peer identifiers that bind the peer devices to the user identity is received from the infrastructure authentication service. A peer-to-peer identifier that binds the selected peer device to the user identity is received from a selected one of the peer devices, and the selected peer device authenticated as associated with the user identity based on receiving the respective peer-to-peer identifier. | 11-19-2009 |
| 20100069389 | NOVEL FORMS OF REBOXETINE - The invention relates to novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride. In various embodiments, the novel crystalline forms may be substantially enantiopure. The preparation and characterization of the novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride is also described. The invention also relates to pharmaceutical compositions containing novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride, which are useful to treat and/or prevent various conditions such as nervous system and pain disorders. | 03-18-2010 |
| 20110275679 | FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL - The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal. | 11-10-2011 |
| 20110275681 | NOVEL SOLID FORMS OF EPALRESTAT - The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic. | 11-10-2011 |
| 20110275682 | NOVEL CHOLINE COCRYSTAL OF EPALRESTAT - The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients. | 11-10-2011 |
| 20110275695 | CRYSTALLINE FORMS OF ZOTEPINE HYDROCHLORIDE - The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these crystalline forms of zotepine hydrochloride is described. The invention also relates to the therapeutic use of the crystalline forms of zotepine hydrochloride to treat central nervous system disorders and to pharmaceutical compositions containing them. | 11-10-2011 |
